A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)

T

Tongji Hospital

Status

Unknown

Conditions

Infection
Spontaneous Bacterial Peritonitis
End Stage Liver Disease

Treatments

Drug: Antibiotics

Study type

Observational

Funder types

Other

Identifiers

NCT03362632
SESLDIP study

Details and patient eligibility

About

Spontaneous bacterial peritonitis (SBP) is a common complication of end-stage liver disease due to various causes. The initial anti-infective medication is appropriate and the patient's survival rate is closely related. Ascitic fluid bacterial culture takes a long time, the positive rate is low, it is difficult to guide the timely use of antimicrobial drugs, empirical medicine based on evidence-based medicine for SBP in patients with end-stage liver disease is essential. The American College of Hepatology and the European Society of Hepatology recommend the use of third-generation cephalosporins as the first choice of empirical therapy in patients with end-stage liver disease associated with community-acquired SBP. Patients with merger of hospital-acquired SBP with piperacillin / tazobactam or carbapenem +/- glycopeptide antibiotics is the first choice for empirical medication. There is no clear recommendation in China. In recent years, the conclusions of international clinical research in this area have been in disagreement with the recommendations. As a key factor in the selection of empirical antibiotics is local bacterial resistance data, these findings are difficult to evidence-based medicine for Chinese doctors. This project intends to observe the efficacy of different initial anti-infective regimens in Chinese patients with end-stage liver disease with SBP and 30-day and 60-day non-liver transplant survival rates, providing evidence-based medical evidence for the empirical use of such patients.

Enrollment

400 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Meet the end-stage liver disease part of the type of standard (including slow plus acute liver failure, chronic liver failure, cirrhosis decompensation);
  • age> 18 years old
  • ascites nucleated cell count> 250 × 106 / L;
  • Unable to obtain ascites specimens or ascites nucleated cells count does not meet the conditions of 3) are required abdominal examination tenderness (+), rebound tenderness (+), abdominal ultrasound can detect ascites, and procalcitonin (PCT) > 0.5ng / ml, hs-CRP> 10ng / ml

Exclusion criteria

  • history of abdominal surgery within 4 weeks;
  • secondary peritonitis;
  • tuberculous peritonitis;
  • Malignant tumor;
  • patients who use hormones or immunosuppressants;
  • AIDS patients;
  • heart failure or respiratory failure;
  • merge other parts of the infection;
  • died within 48h;
  • liver transplantation during observation;
  • Diagnosis of spontaneous bacterial peritonitis is the use of carbapenems or third-generation cephalosporins / enzyme inhibitors, piperacillin / enzyme inhibitor antibiotics

Trial design

400 participants in 2 patient groups

Infection Group
Description:
Patients with end stage liver disease with SBP
Treatment:
Drug: Antibiotics
Non-infection Group
Description:
Patients with end stage liver disease without SBP

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems